Prima BioMed (NASDAQ:IMMP) Share Price Crosses Below 50 Day Moving Average – Here’s What Happened

Prima BioMed Ltd (NASDAQ:IMMP) crossed below its 50-day moving average during trading on Monday. The stock has a 50-day moving average of $6.08 and traded as low as $3.13. Prima BioMed shares last traded at $3.17, with a volume of 6,783 shares.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on IMMP. Jefferies Financial Group upgraded Prima BioMed from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 14th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Prima BioMed in a report on Tuesday, October 6th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Prima BioMed has an average rating of “Hold” and a consensus target price of $110.00.

Prima BioMed Stock Performance

The company’s 50 day moving average is $5.90 and its 200 day moving average is $7.59.

Prima BioMed (NASDAQ:IMMP) last issued its quarterly earnings results on Thursday, July 30th. The biotechnology company reported ($1.80) earnings per share for the quarter. The business had revenue of $3.68 million for the quarter.

Prima BioMed Company Profile

Prima BioMed Limited was an Australian biotechnology company focused on developing immunotherapies for cancer and other serious diseases. The company’s research centered on treatments designed to activate or enhance the immune system’s ability to recognize and attack abnormal cells.

Its principal programs included LAG-3–targeted therapies, including IMP321, later known as eftilagimod alpha or efti, an investigational soluble LAG-3 protein intended to stimulate immune responses when used alone or in combination with other cancer treatments.